PMID- 16042883
OWN - NLM
STAT- MEDLINE
DCOM- 20070907
LR  - 20050726
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 13
IP  - 7
DP  - 2005 Jul
TI  - [Immune response enhanced by genes encoding IFN-alpha 8 and T alpha 1 
      co-inoculated with HBV DNA vaccine].
PG  - 497-500
AB  - OBJECTIVES: To evaluate if the humoral immune response of hepatitis B DNA vaccine 
      pVAX1-S2S could be enhanced by Talpha1 and/or IFNa expression plasmid 
      co-inoculated. METHODS: The following mammalian expression recombinant plasmids 
      were constructed: the plasmid pVAX1-S2S expressing hepatitis B surface antigen 
      S2S, the plasmid pVAX1-T/I co-expressing thymosin a and IFNalpha, the plasmid 
      pVAX1-I/S2S co-expressing IFNalpha and S2S. These plasmids were inoculated 
      intramuscularly into several BALB/c mice groups in different combinations. In the 
      co-immunization group 1 (pVAX1-I/S2S), each mouse was inoculated with 100 microg 
      of pVAX1-I/S2S; in the co-immunization group 2 (pVAX1-S2S) each mouse was 
      co-inoculated with pVAX1-S2S and 50 microg of pVAX1-TI; in the control group each 
      mouse was inoculated with 100 microg of pVAX1-S2S. All the immunizations were 
      boosted at 2 and 4 week intervals; then the serum samples were collected to 
      detect the anti-HBs and anti-preS2 strengths. RESULTS: 3, 5 and 8 weeks after the 
      first inoculation, the positive rates of anti-HBs were 12.5%, 12.5%, 62.5% 
      respectively in the co-immunization group 1 and 25%, 50%, 50% in the 
      co-immunization group 2, while those in the control group were 0, 25%, 37.5%. The 
      titers of anti-preS2 in co-immunization group 2 was 5 times higher than those in 
      the other two groups. CONCLUSION: The data shows that Talpha1 and/or IFNalpha 
      expression plasmid co-inoculated with pVAX1-S2S might act as an adjuvant to 
      enhance the humoral immune response induced by pVAX1-S2S.
FAU - Zhou, Tao-you
AU  - Zhou TY
AD  - Department of Infectious Disease Center, State Key Laboratory of Biotherapy, West 
      China Hospital of Sichuan University, Chengdu 610041, China.
FAU - Zhao, Lian-san
AU  - Zhao LS
FAU - Chen, Min
AU  - Chen M
FAU - Chen, Shou-chun
AU  - Chen SC
FAU - Wang, Song
AU  - Wang S
FAU - Liu, Li
AU  - Liu L
FAU - Tang, Hong
AU  - Tang H
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vaccines, DNA)
RN  - 61512-21-8 (Thymosin)
SB  - IM
MH  - Adjuvants, Immunologic/genetics/*therapeutic use
MH  - Animals
MH  - Female
MH  - Hepatitis B/immunology/therapy
MH  - Hepatitis B Vaccines/*immunology/therapeutic use
MH  - Interferon-alpha/*genetics/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Recombinant Fusion Proteins/immunology
MH  - Thymosin/*genetics/immunology
MH  - Vaccines, DNA/*immunology
EDAT- 2005/07/27 09:00
MHDA- 2007/09/08 09:00
CRDT- 2005/07/27 09:00
PHST- 2005/07/27 09:00 [pubmed]
PHST- 2007/09/08 09:00 [medline]
PHST- 2005/07/27 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2005 Jul;13(7):497-500.